To ensure this doesn't happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Newman told CNBC that Aetna's momentum — which he described as "the tailwinds we're seeing" — accounts for the bulk of the raised revenue target, even as the company keeps a careful eye on persistently high medical costs for the remainder of the year. With the results, CVS extended its run of topping Street expectations to five straight quarters, according to Reuters. A CEO change had come in 2024, a year when the company repeatedly fell short of Wall Street expectations. Revenue from the health services se ...

Brian O. Newman Executive Vice President and Chief Financial Officer Cautionary statement regarding forward looking statements First quarter 2026 May 6, 2026 Earnings Conference Call J. David Joyner Chairman and Chief Executive Officer This presentation includes forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation ("CVS Health"). By their nature, all forward-looking statements are ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to_________ Commission File Number: 001-01011 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) | Delaware | 05-0494040 ...

CVS Health raised its full-year forecast on Wednesday, aided by increased first-quarter earnings in the company's pharmacy management business and strong medical cost controls in its government-sponsored health plans. ...

Exhibit 99.1 CVS HEALTH CORPORATION REPORTS STRONG FIRST QUARTER 2026 RESULTS AND RAISES FULL-YEAR 2026 GUIDANCE WOONSOCKET, RHODE ISLAND, May 6, 2026 - CVS Health Corporation (NYSE: CVS) today announced operating results for the three months ended March 31, 2026. "CVS Health continues to provide what people want most from health care: a connected, convenient, cost-effective engagement experience across our unique collection of businesses. We build trust every day in communities across the country by provid ...

A screen displays the logo and trading information for CVS at the New York Stock Exchange, March 24, 2026. CVS Health on Wednesday blew past first-quarter earnings and revenue estimates and raised its 2026 guidance, as its once-troubled insurance business showed improvement. CVS, which operates the nation's largest pharmacy chain, sees full-year profit coming in between $7.30 and $7.50 per share. That's up from a previous guidance of $7 to $7.20 per share. Earnings per share: $2.57 adjusted vs. $2.20 expect ...

The company attributed much of the improvement to a turnaround at its insurance unit, Aetna. ...

CVS attributed much of the improvement to a turnaround at its insurance unit, Aetna. ...

CVS健康调整药品目录核心决策 - CVS健康宣布自7月1日起在其最常用的药品目录中优先使用低成本、可互换的生物类似药，以替代强生的银屑病药物Stelara [1] - 此项调整由其药房福利管理部门Caremark执行，将转向使用Stelara的生物类似药版本，例如山德士的Pyzchiva和百康生物的Yesintek [2] - 大多数会员将为其治疗支付0美元的自付费用 [2] 决策背后的商业逻辑与行业影响 - 公司高层表示，扩大采用FDA批准的生物类似药能为客户带来显著节约，同时支持更广泛、更经济地获得成熟疗法 [3] - 生物类似药与普通仿制药不同，后者是简单化学药的精确复制品，而前者源于活细胞，无法被完全精确复制 [3] - Caremark正在扩大特定专科治疗领域的生物类似药覆盖范围，包括多发性硬化症和罕见血液疾病的治疗 [4] - 药品目录是在药房福利管理商支持下管理的、健康计划涵盖的处方药列表，该管理商充当雇主和健康计划的中间人 [4] 其他行业动态摘要 - 意大利Banco BPM银行第一季度净利润超出预期，主要受净手续费收入激增推动，抵消了贷款收入下降的影响 [5] - 据金融时报报道，日产汽车将在全球重组中削减10%的欧洲员工 [5] - 美国及其他国家提议达成电子商务协议，以应对世贸组织谈判的深度僵局 [5] - Fiserv公司因金融解决方案业务表现疲软，季度营收未达预期 [5] - 荷兰量子计算公司QuantWare从英特尔等投资者处筹集了1.78亿美元资金 [5]